Physician profile
Stephanie Abrams
NPI 1427160076
$93,635.38
in general payments reported to CMS, 2019-2025
19 companies · $13K in 2025
The $13K reported for 2025 was more than what 94% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $7,000 · 2021: $1,583 · 2022: $5,300 · 2023: $25K · 2024: $27K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $54K · Travel and Lodging: $4,992 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,025 · Food and Beverage: $1,955 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $53,762.50 |
| Travel and Lodging | $4,992.34 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,025.00 |
| Food and Beverage | $1,954.79 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcresta Therapeutics, INC. | $60,014.79 | 2023-2025 | Relizorb |
| Abbvie INC. | $32,726.42 | 2019-2024 | |
| Genzyme Corporation | $325.29 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $104.92 | 2022-2023 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $86.36 | 2023 | Gattex |
| Rhythm Pharmaceuticals, INC. | $64.73 | 2021-2023 | Imcivree |
| Qol Medical, LLC | $56.89 | 2025 | Sucraid |
| Acadia Pharmaceuticals INC | $41.49 | 2023 | Daybue |
| Boston Scientific Corporation | $40.75 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $32.81 | 2024 | Bylvay |
| Allergan, INC. | $24.79 | 2019 | |
| Chiesi USA, INC. | $24.39 | 2019 | |
| Shire North American Group INC | $22.36 | 2019 | |
| Albireo Pharma, INC. | $18.44 | 2023 | Bylvay |
| Capsovision, INC. | $17.71 | 2023 | Capsocam Plus |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $16.42 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $14.20 | 2024 | |
| Travere Therapeutics, INC. | $2.62 | 2019-2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Abrams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.